van der Valk Rikkert

Beckers Henny J M, Schouten Jan S A G, Webers Carroll A B, van der Valk Rikkert, Hendrikse Fred

This study found most glaucoma patients are satisfied with their eye drops, experiencing low side effects and infrequent discontinuation, with common medications showing similar tolerability.

van der Valk Rikkert, Webers Carroll A B, Hendrikse Fred, de Vogel Stefan C, Prins Martin H, Schouten Jan S A G

This study found timolol and latanoprost provide similar IOP reduction in practice. Importantly, routine patient data, beyond baseline IOP, cannot reliably predict individual treatment response for glaucoma management.

Webers Carroll A B, van der Valk Rikkert, Schouten Jan S A G, Zeegers Maurice P, Prins Martin H, Hendrikse Fred

Adding dorzolamide or latanoprost to timolol significantly lowers intraocular pressure further, with latanoprost showing a greater effect, providing effective combination therapy for glaucoma.

van der Valk Rikkert, Schouten Jan S A G, Webers Carroll A B, Hendrikse Fred, Prins Martin H

New glaucoma drugs introduced in 1999 shifted treatment patterns, leading to more combination therapy and significantly lower achieved IOPs for patients, improving glaucoma control.

van der Valk Rikkert, Webers Carroll A B, Schouten Jan S A G, Zeegers Maurice P, Hendrikse Fred, Prins Martin H

This meta-analysis found prostaglandin analogs (bimatoprost, travoprost, latanoprost) and timolol are most effective at lowering intraocular pressure, guiding optimal glaucoma treatment.

van der Valk Rikkert, Schouten Jan S A G, Webers Carroll A B, Beckers Henny J M, van Amelsvoort Ludovic G P M, Schouten Hubert J A et al.

Dutch glaucoma surgeries almost halved (1997-2000) after new drug introduction and treatment protocol changes. This suggests new medications significantly reduced the need for surgery, offering a sustained benefit.